(Q57825105)

English

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

scientific article published on 27 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

based on heuristic

inferred from title

drug interaction

0 references

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Anne M Filppula

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tuija Tapaninen

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

O Kailari

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

P J Neuvonen

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

M Neuvonen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

0 references

publication date

27 June 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

96

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

498-507

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Grapefruit juice inhibits the metabolic activation of clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil greatly increases plasma concentrations of cerivastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Impact of OATP transporters on pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Drug interaction studies: study design, data analysis, and implications for dosing and labeling

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

21 January 2018

Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.141

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2014.141

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24971633%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57825105&oldid=2125865232"